Navigation Links
Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy
Date:3/10/2008

NEW YORK, MARCH 6, 2008 A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a dose-dense regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity. While previous reports evaluating the cardiac effects of breast cancer treatments including trastuzumab and anthracyclines have shown an acceptable safety margin, the new study demonstrates an even lower risk of cardiac toxicity when standard doses of these drugs are administered more frequently over time a treatment plan called dose-dense, which has previously been shown to be a more effective anti-cancer approach.

The researchers used a dose-dense regimen of doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan or Neosar) followed by paclitaxel (Taxol) and found that the regimen when given every two weeks instead of three pairs safely with trastuzumab, a drug that is used to treat breast cancer in women whose tumors contain the protein receptor called HER2.

According to the findings, only 1.4 percent (one patient) of the 70 early-stage breast cancer patients treated with this regimen experienced congestive heart failure after 28 months of follow-up. This rate of cardiac toxicity is lower than the 4 percent threshold that is generally considered acceptable, and still lower than what was found in larger, previously published trials evaluating conventionally scheduled treatment with the use of trastuzumab.

The studys authors concluded that this dose-dense regimen combined with trastuzumab is a safe and effective way to treat women with early-stage HER2-positive breast cancer in the adjuvant setting and there is no need to forgo the use of this regimen because trastuzumab is also being administered.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
212-639-3139
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Page: 1

Related medicine news :

1. Moderate alcohol consumption in middle age can lower cardiac risk
2. CardiacQA Surpasses 20,000 Client Generated Nuclear Cardiology Reports
3. Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results
4. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
5. Cardiac Science Corporation Selects Colubris Networks Wireless Solution for its Portable Electrocardiograph
6. $4 million award to improve detection of acute kidney injury after cardiac surgery
7. Cardiac Science to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
8. Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
9. Diagnostic Centers of America Retains NewsMark Public Relations to Showcase Its Rise as Only Medical Facility in South Florida With Worlds Most Advanced Cardiac Scanner
10. Gene predicts heart attack response and cardiac damage
11. Delray Beach Mayor Commemorates Diagnostic Centers of America (DCA) $2 Million Purchase from Siemens to Become Only Medical Facility in South Florida with Worlds Most Advanced Cardiac Scanner.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... Denver, CO. (PRWEB) , ... August 22, 2017 , ... Each of the past six ... to take attractive pictures of these labels and stickers, demonstrating the variety and creativity of ... great group of label images came in. Now, it's time to announce the winners of ...
(Date:8/22/2017)... ... ... “Wilderness Voices”: a collection of poetry inspired by life on a Kentucky farm and ... Martha McKown, an ordained United Methodist minister with graduate degrees in Religious Education and ... sisters studied High School literature. She loved the early English folk ballads, especially ...
(Date:8/22/2017)... KS (PRWEB) , ... August 22, 2017 , ... TopConsumerReviews.com ... products to fight Fatigue . , As the stress of modern life continually ... up the pace. Constant use of artificial stimulants can trap people in vicious high/low ...
(Date:8/21/2017)... ... August 22, 2017 , ... ... Stevens as a 2017-2018 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting more than ...
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon running has surged ... country. , Outdoor running increases exposure to ultraviolet radiation, a carcinogen that promotes ... melanoma, and only half may be adequately protecting themselves with proper clothing and ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... E.I. Medical Imaging (EIMI) has partnered with ... design the worlds first ultrasound system to be used underwater ... habitat. In preparation for a piece produced by Icon ... Dr. Guttridge approached EIMI with the idea of an underwater ... sharks underwater. EIMI ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 The ... treat rare nervous system diseases, has concluded a worldwide license ... the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing ... in a Phase 2 study conducted in Europe ... the United States ...
Breaking Medicine Technology: